Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04592913 |
| Title | Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies |
Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin |
| Age Groups: | adult | senior |
| Covered Countries | USA | FRA | ESP | DEU | CAN | BEL |